Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

Share Price is delayed by 15 minutes
Get Live Data
68.00    0.00 (0.00%)
Bid:
67.90
Ask:
68.10
Spread: 0.20 (0.295%)
Market Cap: £600.73m
IPO Live PriceLast checked at - London Stock Exchange

Intraday Ip Group Share Chart

Board changes

6 Oct 2021 07:00

RNS Number : 1257O
IP Group PLC
06 October 2021
 

FOR RELEASE ON

06 October 2021

 

 

IP Group plc - Board changes

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), the developer of intellectual property-based businesses, announces that following the successful flotation of the Group's largest holding, Oxford Nanopore Technologies plc, Alan Aubrey, Chief Executive Officer, and Mike Townend, Chief Investment Officer, are retiring and stepping down from the IP Group Board from today.

 

The Board is delighted to announce that Greg Smith, Chief Financial Officer, will succeed Alan as Chief Executive Officer and David Baynes, the Group's Chief Operating Officer, will take on executive responsibility for finance and becomes Chief Financial and Operating Officer.

 

To facilitate an orderly handover and transition, both Alan and Mike will remain as employees, serving their six-month notice periods until 06 April 2022 and as consultants for a minimum of 12 months from 07 April 2022.

 

As referenced in the Group's 2020 Annual Report & Accounts, the Nomination Committee used an external executive search and leadership consultancy to assist in identifying and assessing candidates both internally and externally as part of succession planning. The Committee deferred finalising its recommendation to align the final decision with anticipated events in the portfolio, such as the potential Oxford Nanopore flotation, and to ensure continued stability for the Group during the pandemic. Following the flotation of Oxford Nanopore and the easing of COVID-19 restrictions, the Committee reconvened and its recommendations were unanimously accepted by the Board.

 

Sir Douglas Flint, Chairman of IP Group, said: "On behalf of the Board and the wider IP Group family, I would like to thank both Alan and Mike for the transformational contributions they have made to IP Group over the past 16 and 14 years respectively. During Alan's tenure as CEO, the value of the portfolio has increased more than 28-fold to over £1.2bn* and has produced several companies worth more than £1bn. We are delighted that Greg will step into the role of CEO and lead the Group in its next phase. We are also pleased that Alan and Mike will continue with the Group in a consulting capacity so that the Group can continue to call on their significant experience in the sector. Greg has more than 20 years' experience in financial services, having been in the role of CFO for more than ten years and with IP Group for more than thirteen years. He has played a central role in developing and executing the Group's growth strategy which made him the obvious and unanimous choice to succeed Alan."

 

Alan Aubrey said: "Following the successful flotation of Oxford Nanopore Technologies on the London Stock Exchange, this felt a natural moment to step back. It has been a privilege and an honour to build and lead the team at IP Group and I am proud of all that has been achieved during this time. The Group is in great shape with a strong balance sheet, a portfolio of exciting growth technology companies and opportunities and I am confident that it will go from strength to strength under Greg's leadership. I look forward to continuing working with IP Group in a different capacity going forward and continuing to support the team in the future."

 

Commenting on his new role, Greg Smith said: "It is an exciting time to be taking on the role of CEO at IP Group. The Group benefits from a very strong financial position, a portfolio of growth technology companies and an excellent pipeline. I am looking forward to building on recent successes and I am confident that IP Group will continue to deliver world-changing businesses that have real impact as well as deliver value for all stakeholders."

 

The Group will consult with shareholders this Autumn on remuneration arrangements for the CEO and CFOO as part of the regular triennial review of Directors remuneration policy. IP Group will continue to align the interests of the Executive team with those of shareholders and other stakeholders and will discuss the optimum structure and level required to achieve this as part of the forthcoming consultation. Remuneration arrangements for the departing executive directors will be published on the Company's website and included in the 2021 Annual Report in the usual way.

There are no further updates required under Listing Rule 9.6.13 as a result of this change of roles.

*As at 30 June 2021.

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Liz Vaughan-Adams, Communications

+44 (0) 20 7444 0062/+44 (0) 7979 853802

Charlotte Street Partners

David Gaffney

+44 (0) 7854 609998

Andrew Wilson

+44 (0) 7810 636995

 

Notes for editors

 

About IP Group

 

IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

 

Group holdings in portfolio companies reflect the undiluted beneficial equity interest excluding debt, unless otherwise explicitly stated.

 

For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAVELFBFBLEFBD
Date   Source Headline
19th Oct 20216:31 pmRNSTransaction in Own Shares
19th Oct 20217:00 amRNSTransaction in Own Shares
18th Oct 20217:00 amRNSTransaction in Own Shares
14th Oct 20216:27 pmRNSTransaction in Own Shares
13th Oct 20216:22 pmRNSTransaction in Own Shares
13th Oct 202111:36 amRNSDirector Declaration
13th Oct 20219:03 amRNSHolding(s) in Company
12th Oct 20216:20 pmRNSTransaction in Own Shares
12th Oct 20212:09 pmRNSDirector/PDMR Shareholding
12th Oct 20217:00 amRNSTransaction in Own Shares
11th Oct 20217:41 amRNSTransaction in Own Shares
8th Oct 20217:00 amRNSShare buyback programme
6th Oct 20217:00 amRNSBoard changes
5th Oct 20214:44 pmRNSHolding(s) in Company
30th Sep 20214:11 pmRNSTotal Voting Rights
30th Sep 20217:45 amRNSIP Group generates £84m from Oxford Nanopore IPO
27th Sep 202112:40 pmRNSDirector/PDMR Shareholding
23rd Sep 20213:57 pmRNSFurther re Scrip Dividend
16th Sep 20217:08 amRNSOxford Nanopore confirms ITF; MoU with Oracle
10th Sep 20215:21 pmRNSHolding(s) in Company
8th Sep 202110:53 amRNSDirector/PDMR Shareholding, SAYE scheme
19th Aug 202110:41 amRNSScrip Dividend Reference Price
12th Aug 20215:05 pmRNSDirector Declaration
5th Aug 20217:00 amRNSHalf-yearly results
27th Jul 20217:03 amRNSPortfolio company Artios Pharma raises $153m
22nd Jul 202111:30 amRNSNotice of Results
1st Jul 20217:00 amRNSTotal Voting Rights
28th Jun 20217:30 amRNSDirector/PDMR Shareholding
18th Jun 20219:52 amRNSDirector/PDMR Shareholding
17th Jun 20217:00 amRNSPortfolio company Apollo Therapeutics raises $145m
15th Jun 20218:00 amRNSFurther re Scrip Dividend
9th Jun 202111:29 amRNSResult of AGM
9th Jun 20217:00 amRNSAGM Statement
7th Jun 20217:00 amRNSPortfolio co Iksuda completes $42m financing round
28th May 20213:36 pmRNSDirector/PDMR Shareholding
28th May 202110:00 amRNSJoint venture with China Everbright to launch fund
27th May 20217:00 amRNSPortfolio co Pulmocide completes $92m Series C
26th May 20212:44 pmRNSUpdate on AGM
20th May 202110:01 amRNSScrip Dividend Reference Price
17th May 202112:44 pmRNSAdditional fair value gain of £20m
12th May 202112:08 pmRNSHolding(s) in Company
10th May 202111:15 amRNSInvestor webinars
6th May 20216:13 pmRNSNotice of AGM, Annual Report, Scrip Dividend
6th May 20215:55 pmRNSLTIP & DBSP awards; Director/PDMR shareholding
5th May 20217:00 amRNSPortfolio company Kuur acquired by Athenex
5th May 20217:00 amRNSPortfolio company Inivata acquired by NeoGenomics
4th May 20217:00 amRNSPortfolio company Oxford Nanopore raises £195m
7th Apr 202111:27 amRNSDirector/PDMR Shareholding
31st Mar 20219:15 amRNSHolding(s) in Company
30th Mar 20217:05 amRNSOxford Nanopore announces preparing for IPO in H2

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.